LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the Ladenburg Thalmann 2021 Virtual ... Read More
Latest News
04
Jun2021
04
Jun2021
Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial responses to single-agent FYARRO
Tumor-agnostic registrational trial of FYARRO in mTOR inhibitor-naïve solid tumors with TSC1 or TSC2 inactivating alterations to be initiated by the end of 2021
LOS ANGELES, June 04, 2021 (GLOBE NEWSWIRE) -- ... Read More
June 4, 2021admin
19
May2021
LOS ANGELES, May 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announces the release of an abstract selected for poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting being ... Read More
May 19, 2021admin
17
May2021
Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genes
Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital ... Read More
May 17, 2021admin
11
Jan2021
EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China
Aadi will receive an upfront payment, regulatory and sales milestone payments totaling up to $271M plus royalties
Aadi Bioscience (Aadi), a biopharmaceutical company focusing on precision therapies for genomically defined cancers and EOC Pharma (EOC), a leading oncology specialty ... Read More
January 11, 2021admin
20
Nov2020
25
Jun2020
Rolling submission of U.S. FDA New Drug Application initiated
Long-term follow-up data released at ASCO 2020 for AMPECT study
Independent reviewed ORR of 39%
Long-term, durable ongoing responses with half the responders having ongoing response duration of 25.8 months or longer
Exploratory analysis in patients with TSC2 mutated tumors show ... Read More
June 25, 2020admin